KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

Researchers at the Korea Advanced Institute of Science and Technology have laid out what they describe as the definitive roadmap for turning microbial foods from a laboratory curiosity into a full-scale industrial sector, arguing that the decisive question facing the field is no longer whether such foods can be produced, but which nations and companies can industrialize them first. In a comprehensive analysis published on July 17 in the journal One Earth, a team led by Distinguished Professor Sang Yup Lee of KAIST’s Department of Chemical and Biomolecular Engineering, working with researchers from SilicoBio, a KAIST faculty startup, examined the conditions the microbial food industry must satisfy across manufacturing, market entry, and regulation, and proposed growth strategies for the next-generation protein market.

The study is notable less for introducing a new organism or production technique than for systematically analyzing the gap between laboratory-based core technologies and real-world industry. Rather than reporting a benchtop breakthrough, the researchers assembled an integrated perspective covering manufacturing readiness, market entry strategies, and regulatory responses, framing microbial foods not merely as an alternative protein category but as a potential future biomanufacturing platform. The authors and their institution argue the work could serve as a milestone for strengthening national biomanufacturing competitiveness and for fostering a global sustainable food industry.

Microbial foods themselves are far from a speculative concept. Fermentation has long been used to produce bread, beer, cheese, and other staples, and the modern industry builds on that heritage by engineering microorganisms to yield protein directly or to synthesize specific food components. What has changed is the availability of tools such as systems metabolic engineering and synthetic biology, which allow researchers to redesign microbial metabolism with increasing precision. Yet the KAIST team’s central observation is that the explosion of laboratory capability has not been matched by equivalent progress in industrialization, leaving a gap between what can be demonstrated in a flask and what can be manufactured profitably in a plant.

At the heart of the analysis is the claim that competition in the microbial food industry is shifting from laboratory-level productivity toward what the researchers call manufacturing readiness—the level at which a technology proven in the lab can be reliably produced at industrial scale. According to the team, four factors will largely determine the pace of commercialization: stable raw material supply and quality control; the control and safety assurance of non-model microorganisms; the reduction of downstream processing costs; and regulatory compliance for byproduct recycling. Each of these, the researchers contend, represents a bottleneck that must be resolved before microbial foods can achieve the scale and price points required for mass markets.

Some of the terminology the researchers rely on underscores how much of the challenge lies beyond the Petri dish. Non-model microorganisms, for instance, are defined as organisms with high industrial potential but insufficient accumulated research infrastructure—promising candidates whose behavior at scale remains less predictable than that of well-characterized workhorse strains. Downstream processing refers to the sequence of separating, purifying, concentrating, and drying target components after fermentation, steps the team identifies as a major cost center. By highlighting these stages, the analysis signals that purification and finishing operations, often overlooked in early-stage research, may weigh as heavily on commercialization timelines as fermentation yields themselves. Raw material supply carries similar weight, because fermentation processes typically require large, consistent quantities of sugars and other feedstocks, and variations in quality or price can ripple through the entire production chain.

The researchers also emphasize that future competitiveness will depend less on the excellence of any single technology and more on the ability to build what they term an integrated manufacturing platform: a production system that operates the entire process as one connected framework, from strain development and large-scale fermentation through purification, quality control, and product formulation. Their reasoning is that the individual choices along that chain are tightly coupled. Even for the same microbial food product, the choice of raw material can affect pretreatment costs and quality variability, while the choice of strain and fermentation process can greatly influence production cost, energy use, and product quality. Companies that optimize these variables in isolation, the team concludes, will lose to those that optimize them together—which is why the speed with which firms can construct integrated platforms will define industrial winners.

Turning to demand, the researchers drew on consumer surveys and industry cases to identify the conditions for market success, and their findings caution against assuming that sustainability alone will sell microbial foods. Consumers, the analysis found, place importance on taste, texture, familiarity, and safety, meaning products must compete on eating experience rather than environmental virtue. Food manufacturers, for their part, value functionality that can be applied to actual products, while companies and investors weigh the predictability of regulatory approval procedures and the speed of market entry as especially important considerations. In other words, the microbial food market has entered an industrial stage in which technology alone is insufficient; product development capability and regulatory readiness are evaluated alongside it. This layered set of expectations helps explain why several early entrants in the alternative protein space have struggled: a compelling sustainability narrative has not reliably translated into repeat purchases when eating experience or price fell short.

Beyond its market analysis, the study makes a broader conceptual argument: microbial foods should not be viewed merely as an alternative protein industry. The researchers suggest the field has the potential to become a core platform for precision fermentation-based functional food ingredients, high-value biomaterials, and circular biomanufacturing. Precision fermentation, as they define it, uses microorganisms to selectively produce specific proteins or functional substances, while circular biomanufacturing describes a sustainable production system that uses byproducts and renewable resources to create new bio-based products. Under this framing, microbial foods could become not just a future food source but a new production system linking the global food, materials, and biomanufacturing industries. The circular element is particularly significant for regulatory purposes, since waste streams generated in one part of the process may be routed into another only if recycling pathways meet compliance requirements.

The proposed industrialization strategy is closely aligned with the business direction of SilicoBio, the KAIST faculty startup that participated in the joint research. Founded in June 2025 by Sang Yup Lee, a scholar widely recognized in synthetic biology, SilicoBio focuses on connecting laboratory-level achievements in systems metabolic engineering to real industrialization. The company combines KAIST’s core technologies with the industrialization experience of personnel drawn from CJ BIO, giving it capacity to review strain design as well as industrial-scale fermentation and scale-up, material purification and product development, pilot production, and process validation. Scale-up, in this context, refers to the expansion of production from laboratory scale to industrial scale—precisely the transition the One Earth paper identifies as the industry’s central hurdle.

SilicoBio is already acting on the study’s manufacturing readiness strategy, working to build a platform that connects microbial proteins and functional food ingredients to industrial-scale fermentation, scale-up, and product development. A company representative said the goal is to connect the industrialization strategy proposed in the study to actual production and commercialization, adding that SilicoBio intends to build a platform capable of stably producing microbial-based next-generation foods and functional biomaterials. The company is pursuing a phased commercialization strategy that begins with next-generation protein products and expands into functional ingredients and, eventually, new drug and novel material candidates.

The research comes as competition over synthetic biology and biomanufacturing intensifies globally, a dynamic Lee highlighted in his comments on the work. “As global competition surrounding synthetic biology and biomanufacturing intensifies, microbial foods are growing into a key industry that will shape national biomanufacturing competitiveness beyond future food,” he said. He added that going forward, competitiveness will be determined by how quickly an industrialization ecosystem can be built that connects core technologies to real production and markets—a formulation that places ecosystem construction, rather than any individual invention, at the center of national strategy. That framing reflects a wider policy conversation in which governments increasingly treat biomanufacturing capacity as strategic infrastructure, akin to semiconductor fabrication, because it underpins supply chains for food, medicine, and materials.

The study, published under the title “Microbial foods as scalable platforms toward a circular protein economy for sustainable nutrition,” lists doctoral student Seok Yeong Jung of the Department of Chemical and Biomolecular Engineering as first author, with SilicoBio researchers including Sol Choi and Jun-Woo Kim—also affiliated with Inha University—among the co-authors. The work was supported by South Korean public programs: the “Development of Next-Generation Biorefinery Core Technologies to Lead the Biochemical Industry” project under the Ministry of Science and ICT’s Petroleum-Alternative Eco-Friendly Chemical Technology Development Program, and the “Advancement of a Synthetic Biology-Based Industrial Cell Factory Platform and Commercialization of High-Value Functional Biomaterials” project under the Deep Science Startup Activation Support Program administered by the Korea Commercialization Promotion Agency for R&D Outcome. The dual funding profile illustrates how South Korea has tied basic biochemical research directly to startup formation and commercialization pipelines.

As with any strategy analysis, the study’s value will ultimately rest on execution rather than prescription. The researchers themselves frame their contribution as identifying the factors that will determine the pace of commercialization—raw material security, non-model organism safety, downstream cost reduction, byproduct recycling compliance, and regulatory predictability—not as solved problems. But by mapping the connected challenges of manufacturing, markets, and regulation in a single framework, the KAIST team has articulated a testable proposition for the industry: that the first microbial food producers to master integrated manufacturing platforms, rather than the inventors of the best strains, will define the next-generation protein economy.